Board of Directors

Dr. Borellini has more than 25 years of executive management experience in the pharmaceutical and biotechnology industries with a focus on the global development of targeted oncology drugs from preclinical to commercial stage.

Dr. Borellini most recently served as Chief Executive Officer for Acerta Pharma, overseeing the successful development and approval of Calquence® (acalabrutinib). Prior to this, Dr. Borellini held key senior level positions within AstraZeneca including Global Franchise Head, Hematology, where she led the global development, approval, and commercialization of Tagrisso® (osimertinib). Prior to AstraZeneca, Dr. Borellini held roles of increasing responsibility at Genentech, a member of the Roche Group, where she led the development, approval and launch of Zelboraf® (vemurafenib). Dr. Borellini also served as the program leader for Herceptin® (trastuzumab) and Tarceva® (erlotinib).

In addition to Pliant, Dr. Borellini currently serves on the Board of Directors of Cantargia AP, Kartos Therapeutics and Revolution Medicines. Dr. Borellini received a Ph.D. in Pharmaceutical Chemistry and Technology from the University of Modena.